Immunotherapies are increasingly used to treat advanced cancers and can extend survival in some patients. The potential for longer survival may inflate prognosis expectations among patients and caregivers and delay palliative care. This review sought to identify issues impacting patients and caregivers that influence specialized palliative care use in the context of immunotherapies. A scoping review was conducted with guidance from the JBI Manual for Evidence Synthesis. Studies were identified using MEDLINE, EMBASE, CINAHL Complete, AgeLine, Cochrane Library, and APA PsycINFO, without any database filters or limiters. Inclusion criteria included palliative care utilization among adult cancer patients receiving immunotherapy and their family caregivers in any geographical or specialty setting. The protocol was registered in the Open Science Framework. Using Covidence, 11 898 studies were screened by reviewers, with 10 studies meeting inclusion criteria. Themes of patient and family considerations that affect the use of specialized palliative care included (1) understanding of disease/treatment, (2) hope/optimism, (3) communication barriers, and (4) emotional distress and uncertainty. This review is one of the first to identify issues impacting patients receiving immunotherapies and their families. Findings have implications for nurse communication, education, and psychosocial support with advanced cancer patients and families receiving immunotherapies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/NJH.0000000000001111 | DOI Listing |
Health Sociol Rev
March 2025
Department of Health, VIVE - The Danish Center for Social Science Research, Copenhagen, Denmark.
Integrating palliative care into the trajectories of patients with incurable cancer has been a priority for years. Yet, the intended outcomes of this integration remain elusive. Many patients with advanced cancer continue to receive so-called aggressive treatments in the end-of-life phase or miss out on specialised palliative care entirely.
View Article and Find Full Text PDFFront Immunol
March 2025
Department of Dermatology, Gesundheit Nord Klinikverbund Bremen, Bremen, Germany.
Background: Although systemic therapies have improved considerably over the last decade, up to 50% of patients with metastatic melanoma still die due to disease progression. Oncological treatment at the end-of-life phase is challenging. The aim of this study was to investigate the frequency and type of systemic therapy received by melanoma patients in their end-of-life phase.
View Article and Find Full Text PDFCureus
February 2025
Department of Emergency Medicine, Massachusetts General Hospital, Boston, USA.
Background Falls are a leading cause of unintentional death among adults aged 65 and above and are associated with significant injuries and healthcare costs. Older adults frequently present to the emergency department (ED) for falls. However, ED clinicians rarely focus on preventing future falls, given the lack of time and resources.
View Article and Find Full Text PDFJ Hepatocell Carcinoma
March 2025
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Hepatocellular carcinoma (HCC) is a complex cancer that generally arises in the context of cirrhosis. Patients with HCC have symptom burden and impact on health-related quality of life (HRQOL) resulting from underlying liver disease, HCC, and cancer treatments. Patient-reported outcome (PRO) measures may improve the management of patients with HCC by accurately capturing the patient perspective, informing prognosis, guiding treatment decisions, and supporting symptom based and palliative care.
View Article and Find Full Text PDFCurr Opin Oncol
February 2025
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Purpose Of Review: Relapsed or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a deadly disease that historically was treated with palliative chemotherapy-based regimens. Since 2019, immunotherapy-based regimens have become the standard of care for 1st line treatment in this disease. Over the last several years, there have been numerous studies conducted with novel combination therapies for R/M HNSCC but there has not yet been a new standard of care.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!